CAMBRIDGE, Mass., May 5 /PRNewswire-FirstCall/ --
Transkaryotic Therapies, Inc. (Nasdaq: TKTX) today announced the appointment
of Mr. Gregory D. Perry as the company's new Vice President, Finance and Chief
Financial Officer, effective May 27, 2003. In this role, Mr. Perry will have
overall responsibility for all financial matters of the company and will
report directly to Michael J. Astrue, TKT's President and Chief Executive
Officer.
"Greg has a twenty year record of demonstrated financial success in
quality organizations. His global operating experience and his strong
operational finance skills will contribute tremendously as we grow our
business," said Mr. Astrue. "We are extremely pleased that Greg has decided
to join our management team and we look forward to his many contributions at
TKT."
Mr. Perry joins TKT from PerkinElmer, Inc. where he most recently served
as Senior Vice President, Finance and Business Development, Life Sciences. In
this position he was responsible for the financial management of PerkinElmer's
$500 million drug discovery tools and genetic disease screening business, as
well as information technology and business development activities. Prior to
joining PerkinElmer, Mr. Perry was Chief Financial Officer of the Automotive
Aftermarket Products Group at Honeywell where he played a major role in
rebuilding their finance team and successfully closed the acquisition of
Prestone Products, the largest acquisition by Honeywell at that time. During
a fourteen-year tenure at General Electric, Mr. Perry held numerous positions
of increasing responsibility in finance and business development, most
recently as Chief Financial Officer of GE Medical Systems, Europe,
headquartered in Paris, France. Mr. Perry, 42, received a B.A. in Economics
and Political Science from Amherst College.
About TKT
TKT is a biopharmaceutical company developing therapeutics for the
treatment of rare genetic diseases caused by protein deficiencies. The
company currently markets one product, Replagal(TM) (agalsidase alfa) for the
treatment of Fabry disease in the European Union and certain other countries.
TKT is headquartered in Cambridge, Massachusetts and has a majority-owned
subsidiary in Sweden, TKT Europe-5S AB, which is responsible for European
sales and marketing activities of Replagal. Additional information on TKT is
available on the company's website at http://www.tktx.com.
This press release contains forward-looking information regarding TKT's
management structure, as well as statements containing the words "believes,"
"anticipates," "plans," "expects," "will," and similar expressions. There are
a number of important factors that could cause the company's actual results to
differ materially from those indicated by such forward-looking statements,
including whether TKT will be able to successfully manage its financial
operations, and other factors set forth under the caption "Certain Factors
That May Affect Future Results" in the company's Annual Report on Form 10-K
for the year ended December 31, 2002, which is on file with the Securities and
Exchange Commission and are incorporated herein by reference. The company
does not undertake any obligation to update any forward-looking statements.
Replagal(TM) is a trademark of Transkaryotic Therapies, Inc.
CONTACT:
Justine E. Koenigsberg
Director, Corporate Communications
(617) 349-0271
SOURCE Transkaryotic Therapies, Inc.
 back to top
Related links:
http://www.tktx.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/comp/120657.html
CONTACT:
Justine E. Koenigsberg, Director, Corporate
Communications of TKT, +1-617-349-0271
|
